Compare CNM & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNM | IBRX |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.2B |
| IPO Year | 2021 | 2015 |
| Metric | CNM | IBRX |
|---|---|---|
| Price | $42.66 | $6.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $54.29 | $14.25 |
| AVG Volume (30 Days) | 2.0M | ★ 12.5M |
| Earning Date | 12-08-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.45 | ★ 38.71 |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $7,647,000,000.00 | $113,288,000.00 |
| Revenue This Year | $2.51 | $99.98 |
| Revenue Next Year | $4.23 | $108.29 |
| P/E Ratio | $32.76 | ★ N/A |
| Revenue Growth | 2.77 | ★ 668.31 |
| 52 Week Low | $39.42 | $1.95 |
| 52 Week High | $59.66 | $12.43 |
| Indicator | CNM | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 35.32 |
| Support Level | $40.85 | N/A |
| Resistance Level | $43.51 | $8.62 |
| Average True Range (ATR) | 1.76 | 0.55 |
| MACD | -0.32 | -0.23 |
| Stochastic Oscillator | 6.20 | 14.11 |
Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.